Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-CHOP versus bortezomib-R-CAP in young patients with poor-risk diffuse large B-cell lymphoma
2012-005138-12Phase 2Completed
- Sponsor
- GELTAMO
- Start
- Jan 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bortezomib, rituximab, cyclophosphamide, doxorubicin, prednisone and 1 more in diffuse large B-cell lymphoma (DLBCL) and mature B-cell lymphoma (2 arms), sponsored by GELTAMO. Primary endpoint: Proportion of patients with event-free survival at 2 years. Started Jan 2013; status: completed.
02
Drugs
bortezomibrituximabcyclophosphamidedoxorubicinprednisone
03
Conditions
diffuse large B-cell lymphoma (DLBCL)mature B-cell lymphoma
Beyond the preview
Go deeper on 2012-005138-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005138-12.